David van Duin1, Eric Cober2, Sandra S Richter3, Federico Perez4, Robert C Kalayjian5, Robert A Salata6, Scott Evans7, Vance G Fowler8, Keith S Kaye9, Robert A Bonomo10. 1. Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA david_vanduin@med.unc.edu. 2. Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH, USA. 3. Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA. 4. Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA. 5. Department of Medicine, MetroHealth Medical Center, Cleveland, OH, USA. 6. Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA. 7. Department of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, USA. 8. Division of Infectious Diseases, Duke University, Durham, NC, USA. 9. Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, MI, USA. 10. Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH, USA Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Abstract
OBJECTIVES: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an important healthcare-associated pathogen. We evaluated the impact of CRKP strain type and treatment on outcomes of patients with CRKP bacteriuria. PATIENTS AND METHODS: Physician-diagnosed CRKP urinary tract infection (UTI)-defined as those patients who received directed treatment for CRKP bacteriuria-was studied in the multicentre, prospective Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRaCKle) cohort. Strain typing by repetitive extragenic palindromic PCR (rep-PCR) was performed. Outcomes were classified as failure, indeterminate or success. Univariate and multivariate ordinal analyses to evaluate the associations between outcome, treatment and strain type were followed by binomial analyses. RESULTS: One-hundred-and-fifty-seven patients with physician-diagnosed CRKP UTI were included. After adjustment for CDC/National Healthcare Safety Network (NHSN)-defined UTI, critical illness and receipt of more than one active antibiotic, patients treated with aminoglycosides were less likely to fail therapy [adjusted OR (aOR) for failure 0.34, 95% CI 0.15-0.73, P=0.0049]. In contrast, patients treated with tigecycline were more likely to fail therapy (aOR for failure 2.29, 95% CI 1.03-5.13, P=0.0425). Strain type data were analysed for 55 patients. The predominant clades were ST258A (n=18, 33%) and ST258B (n=26, 47%). After adjustment for CDC/NHSN-defined UTI and use of tigecycline and aminoglycosides, infection with strain type ST258A was associated with clinical outcome in ordinal analysis (P=0.0343). In multivariate binomial models, strain type ST258A was associated with clinical failure (aOR for failure 5.82, 95% CI 1.47-28.50, P=0.0113). CONCLUSIONS: In this nested cohort study of physician-diagnosed CRKP UTI, both choice of treatment and CRKP strain type appeared to impact on clinical outcomes.
OBJECTIVES:Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an important healthcare-associated pathogen. We evaluated the impact of CRKP strain type and treatment on outcomes of patients with CRKP bacteriuria. PATIENTS AND METHODS: Physician-diagnosed CRKP urinary tract infection (UTI)-defined as those patients who received directed treatment for CRKP bacteriuria-was studied in the multicentre, prospective Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRaCKle) cohort. Strain typing by repetitive extragenic palindromic PCR (rep-PCR) was performed. Outcomes were classified as failure, indeterminate or success. Univariate and multivariate ordinal analyses to evaluate the associations between outcome, treatment and strain type were followed by binomial analyses. RESULTS: One-hundred-and-fifty-seven patients with physician-diagnosed CRKP UTI were included. After adjustment for CDC/National Healthcare Safety Network (NHSN)-defined UTI, critical illness and receipt of more than one active antibiotic, patients treated with aminoglycosides were less likely to fail therapy [adjusted OR (aOR) for failure 0.34, 95% CI 0.15-0.73, P=0.0049]. In contrast, patients treated with tigecycline were more likely to fail therapy (aOR for failure 2.29, 95% CI 1.03-5.13, P=0.0425). Strain type data were analysed for 55 patients. The predominant clades were ST258A (n=18, 33%) and ST258B (n=26, 47%). After adjustment for CDC/NHSN-defined UTI and use of tigecycline and aminoglycosides, infection with strain type ST258A was associated with clinical outcome in ordinal analysis (P=0.0343). In multivariate binomial models, strain type ST258A was associated with clinical failure (aOR for failure 5.82, 95% CI 1.47-28.50, P=0.0113). CONCLUSIONS: In this nested cohort study of physician-diagnosed CRKP UTI, both choice of treatment and CRKP strain type appeared to impact on clinical outcomes.
Authors: M S Ramirez; G Xie; S H Marshall; K M Hujer; P S G Chain; R A Bonomo; M E Tolmasky Journal: Clin Microbiol Infect Date: 2012-05-02 Impact factor: 8.067
Authors: Bryan T Alexander; Jonas Marschall; Robert J Tibbetts; Elizabeth A Neuner; W Michael Dunne; David J Ritchie Journal: Clin Ther Date: 2012-06 Impact factor: 3.393
Authors: D van Duin; E D Cober; S S Richter; F Perez; M Cline; K S Kaye; R C Kalayjian; R A Salata; S R Evans; V G Fowler; R A Bonomo Journal: Clin Microbiol Infect Date: 2014-12-12 Impact factor: 8.067
Authors: Matthew Hoffmann; William DeMaio; Ronald A Jordan; Rasmy Talaat; Dawn Harper; John Speth; JoAnn Scatina Journal: Drug Metab Dispos Date: 2007-05-30 Impact factor: 3.922
Authors: Suzana Meira Ribeiro; César de la Fuente-Núñez; Beverlie Baquir; Célio Faria-Junior; Octávio L Franco; Robert E W Hancock Journal: Antimicrob Agents Chemother Date: 2015-04-20 Impact factor: 5.191
Authors: Julia A Messina; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Nikole M Scalera; Yohei Doi; Keith S Kaye; Scott Evans; Robert A Bonomo; Vance G Fowler; David van Duin Journal: Infect Control Hosp Epidemiol Date: 2015-12-21 Impact factor: 3.254
Authors: C Hauck; E Cober; S S Richter; F Perez; R A Salata; R C Kalayjian; R R Watkins; N M Scalera; Y Doi; K S Kaye; S Evans; V G Fowler; R A Bonomo; D van Duin Journal: Clin Microbiol Infect Date: 2016-02-03 Impact factor: 8.067
Authors: Laura J Rojas; Madiha Salim; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Steve Marshall; Susan D Rudin; T Nicholas Domitrovic; Andrea M Hujer; Kristine M Hujer; Yohei Doi; Keith S Kaye; Scott Evans; Vance G Fowler; Robert A Bonomo; David van Duin Journal: Clin Infect Dis Date: 2017-03-15 Impact factor: 9.079
Authors: Sangeeta Sastry; Lloyd G Clarke; Hind Alrowais; Ashley M Querry; Kathleen A Shutt; Yohei Doi Journal: Antimicrob Agents Chemother Date: 2015-09-14 Impact factor: 5.191
Authors: Federico Perez; Nadim G El Chakhtoura; Krisztina M Papp-Wallace; Brigid M Wilson; Robert A Bonomo Journal: Expert Opin Pharmacother Date: 2016-03-09 Impact factor: 3.889